CI&T, Inc. Class A CINT 深 沪
已收盘 04-02 16:00:00 美东时间
5.02
0.000
0.00%
华盛通- 最 高5.05
- 今 开4.88
- 成交量 4.07万股
- 最 低 4.86
- 昨 收 5.02
- 总市值 6.76亿
- 52周最高 7.0864
- 市盈率 静 16.49
- 换手率 0.03%
- 52周最低 3.98
- 委 比 72.41%
- 总股本 1.35亿
- 历史最高 22.50
- 量 比 0.69
- 振 幅 3.78%
- 历史最低 3.3397
- 每 手 1
- 风险率 0.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
Canaccord Genuity Maintains Buy on CI&T, Raises Price Target to $7
Canaccord Genuity analyst Luke Morison maintains CI&T (NYSE:CINT) with a Buy and raises the price target from $6 to $7.
03-13 01:15
CI&T Sees Q1 Sales $134.700M vs $130.348M Est
CI&T (NYSE:CINT) sees Q1 sales of $134.700 million vs $130.348 million analyst estimate.
03-12 04:24
CI&T shares are trading higher after the company reported better-than-expected Q4 financial results.
CI&T shares are trading higher after the company reported better-than-expec...
03-12 04:22
CI&T Q4 Adj. EPS $0.14 Beats $0.10 Estimate, Sales $134.277M Beat $131.372M Estimate
CI&T (NYSE:CINT) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.10 by 41.41 percent. This is a 40 percent increase over earnings of $0.10 per share from the same period
03-12 04:17
Earnings Scheduled For March 11, 2026
Companies Reporting Before The Bell • Sprinklr (NYSE:CXM) is estimated to repor...
03-11 19:11
A Preview Of CI&T's Earnings
CI&T (NYSE:CINT) will release its quarterly earnings report on Wednesday, 2...
03-10 23:01
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
JP Morgan Maintains Overweight on CI&T, Lowers Price Target to $6
JP Morgan analyst Puneet Jain maintains CI&T (NYSE:CINT) with a Overweight and lowers the price target from $7 to $6.
02-19 00:25
美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
